
Recurrence and Complication Rates among Current Pterygium Treatment Techniques: Pre-operative Subpterygeal Mitomycin-C Injection, Intraoperative Mitomycin C Application and Pterygium Excision with Conjunctival Autograft
Author(s) -
Archimedes Lee D. Agahan,
Theresa Gladiola B. Merca,
Jose V. Tecson,
Minnette A. Panganiban
Publication year - 2020
Publication title -
acta medica philippina/acta medica philippina
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.128
H-Index - 4
eISSN - 2094-9278
pISSN - 0001-6071
DOI - 10.47895/amp.v54i5.2242
Subject(s) - pterygium , medicine , mitomycin c , complication , surgery , group b , randomized controlled trial , significant difference
Objective. This study aims to determine recurrence and complication rates among patients who underwent threecurrent pterygium treatment techniques: preoperative subpterygeal injection of mitomycin C, intraoperativeapplication of mitomycin with pterygium excision and pterygium excision with conjunctival autograft.
Methods. This is a randomized controlled clinical trial in a tertiary hospital. We included patients with diagnosedprimary pterygium and who underwent either: A = pre-operative injection of 0.02% mitomycin C one month prior topterygium excision; B = pterygium excision with intraoperative mitomycin C application; or C = pterygium excisionwith conjunctival autograft.
Results. We included 111 patients: a total of 120 eyes randomized to 3 groups (A, B, C) at 40 eyes per group.After 24 months of follow-up, there was no significant difference in the recurrence rates among the groups (6/40[15%] in groups A and B and 2/40 cases [5%] in group C; P=0.29). No complications were noted in groups B and C,while 1 case of scleral thinning was noted in group A. There was no significant difference in the complication ratesamong the three procedures (P=1.00).
Conclusion. There were no significant differences in the recurrence and complication rates among the three techniques. Careful patient selection and follow-up are recommended to prevent complications such as scleral thinning.